Swiss healthcare giant Roche has introduced a digital medical algorithm suite called navify Algorithm Suite that generates patient-centric insights to aid in earlier diagnosis of cancer and other medical conditions. The platform was unveiled at the HIMSS Global Conference in Chicago, USA, from April 17-21, 2023. Medical algorithms are evidence-based decision-making tools used by physicians in the diagnosis, treatment, and monitoring of patients to optimize care, increase early diagnosis, and adhere to guidelines.
The platform offers labs and hospitals one platform to connect easily to digital medical algorithms from a diverse range of innovators. Simultaneously, navify Algorithm Suite also offers universities and other providers of digital algorithms a direct channel to distribute their proven innovations to practising physicians in markets worldwide.
The navify Algorithm Suite complies with GDPR regulations in Europe as well as HIPAA in the USA, and it is designed to be embedded in existing healthcare workflows and information systems for optimal information security management. The first algorithms in the suite focus on oncology, specifically a pre-screening algorithm to identify at-risk healthy people for colorectal cancer and an algorithm intended to aid in the diagnosis of early stage Hepatocellular Carcinoma (HCC) in patients with chronic liver disease.
“With navify Algorithm Suite, clinicians can easily order the medical algorithms they need from Roche and other providers to get enhanced insights that improve patient care,” said Moritz Hartmann, Global Head of Roche Information Solutions at Roche Diagnostics.
Roche believes that as healthcare data is set to grow, digital medical algorithms can generate actionable insights that physicians can use to deliver personalised healthcare. Additional algorithms for oncology, cardiology, and other diseases, such as lung and infectious diseases, are already in the pipeline. The navify Algorithm Suite is currently available in Europe and Asia-Pacific.